19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Right Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Common Eye Conditions Tied to Higher Risk for DementiaMultigenerational Study Finds Links Between ADHD, Dementia RiskMost Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyCould Traffic Noise Raise Your Odds for Dementia?AHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

An ALS Drug Shows Early Promise Against Alzheimer's

HealthDay News
by Robert Preidt
Updated: Aug 2nd 2021

new article illustration

MONDAY, Aug. 2, 2021 (HealthDay News) -- Could a drug used to treat amyotrophic lateral sclerosis (ALS) help people with mild Alzheimer's disease?

The results of a small new study suggest the strategy could work.

Riluzole has been used for more than 20 years to slow the progression of ALS, commonly called Lou Gehrig's disease. This phase 2 study found that the drug slowed brain metabolic decline and had a positive effect on cognition in people with mild Alzheimer's.

It included 50 patients ages 50 to 90 who received either the drug (26) or a placebo (24) twice daily for six months.

"Using two types of brain scans as biomarkers -- this study was able to measure improvements in brain metabolism among treated patients and correlate those improvements with cognitive changes and disease progression," said study co-author Dr. Howard Fillit, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation.

"It is a repurposed drug, which helps speed the research process. It targets an important and understudied biological mechanism that goes awry with aging, and the rigorous design of this trial measured both biomarker and clinical outcomes," Fillit noted in a foundation news release.

Riluzole targets a neurotransmitter in the brain called glutamate, which plays a crucial role in the ability of nerve cells to send signals to one another. Glutamate dysregulation is believed to start a cycle of toxicity involved in Alzheimer's disease, the researchers said.

The study found significant changes in glutamate levels in patients who received the drug. Rates of adverse events were the same among patients who took riluzole and those who took the placebo.

The results were recently published online in the journal Brain.

These findings support a phase 3 trial with larger numbers of patients followed for a longer period of time to further assess the safety and efficacy of the drug in Alzheimer's patients, said lead investigator Dr. Ana Pereira, assistant professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai in New York City.

More information

The Alzheimer's Association has more on Alzheimer's disease.

SOURCE: Alzheimer's Drug Discovery Foundation, news release, July 28, 2021